Galmed Pharmaceuticals Ltd. GLMD 深 滬
已收盤 07-31 16:00:00 美东时间
0.621
+0.022
+3.67%
華盛通- 最 高0.621
- 今 開0.6042
- 成交量 14.08万股
- 最 低 0.5405
- 昨 收 0.599
- 總市值 513.13万
- 52周最高 1.65
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 0.4111
- 委 比 -98.50%
- 總股本 826.30万
- 歷史最高 4870.80
- 量 比 0.20
- 振 幅 13.44%
- 歷史最低 0.4111
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galmed Pharma Announces Continued Advancement Of Aramchol As Potential Disease-Modifying Therapy For Parkinson's Disease, Reporting Significant Progress In Development Of New Aramchol ODF Formulation
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was developed demon...
07-28 19:09
Galmed Pharmaceuticals Announces Breakthrough Development Of New Aramchol-Based Lipid Nanoparticles Formulation For Targeted Delivery To The Heart
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a major driver ...
07-16 19:35
Galmed Agrees With Acquisition Target Colospan To Increase The Cash Portion Of Purchase Price By $800K In Lieu Of Issuing $2M In Shares
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ:GLMD) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate reimbursement in Germany Strategic and Financial Highlights Restructured Anti-Dilutive Financial T...
06-22 19:30
Galmed Pharmaceuticals Ltd.宣布调整Colospan Ltd.收购条款 优先推进CG-100欧洲商业化 保障股东价值并完成收购
纳斯达克上市药企加尔梅德（GLMD）完成对商业化阶段医疗器械企业科隆 span的收购，后者成为其全资子公司。 本次收购调整原反稀释财务条款：取消原定交易完成时发...
06-22 19:06
Galmed Reports Preclinical Results for Heart Disease Drug Combination, Study Identifies New Pathway Linked to Cardiac Fibrosis
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, today announced
06-02 19:38
Galmed Pharmaceuticals Announces Milestone Results From Phase 1 PK Study In Healthy Subjects; 400mg AM Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid 300mg
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling:Production of GMP clinical batch for Galmed's upcoming clinical trialsSolidification and
05-14 19:38
Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a
05-06 19:37
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.
04-09 23:04
Galmed Pharmaceuticals shares are trading higher after the company announced the development of a brain penetrating new formulation of Aramchol.
Galmed Pharmaceuticals shares are trading higher after the company announced th...
04-09 20:39
